Brain implant study tests new epilepsy drug
NCT ID NCT07125261
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 29 times
Summary
This early-phase study tested a new drug called BHV-7000 in 5 people with epilepsy who have a brain implant (RNS) that records brain activity. The goal was to see if the drug reduces abnormal electrical activity linked to seizures. Participants took the drug for 4 weeks, and their brain recordings were compared to a 90-day period before the drug and a 4-week period after stopping it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yale Comprehensive Epilepsy Center
New Haven, Connecticut, 06520, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.